RxAccess Partners

Overview

RxAccess Partners is a woman-owned boutique market-access consultancy serving small-to-mid biotech launches that want senior payer-strategy and patient-support attention from a compact team rather than a large multi-function consultancy. Founded in 2023; legal entity RxAccess Partners LLC; headquartered in Brooklyn, NY.

RxAccess is not built to compete with Trinity, IQVIA, or Precision AQ on scale, AET-panel access, or proprietary data tooling. It is built for teams that want a senior advisor to shape access strategy, payer-facing content, and patient-support architecture without buying a large consultancy.

Market Access Capability Model

The framework below standardizes how Rx Almanac evaluates market-access-consulting capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, RxAccess Partners is evaluated as woman-owned boutique market-access consultancy serving small-to-mid biotech launches that want senior payer-strategy and patient-support attention from a compact team rather than a large multi-function consultancy.

Capability	Buyer should compare	RxAccess Partners readout
Payer landscape and access strategy	Payer segmentation, formulary expectations, coverage barriers, benefit design, and access scenario planning.	Core. Pre-launch payer strategy and access-landscape assessment are the documented anchor offerings.
Pricing, contracting, and GTN strategy	WAC strategy, rebate design, contracting scenarios, GTN forecasting, channel economics, and net-price risk.	Core. Pricing/contracting strategy and gross-to-net support are documented services.
HEOR, value dossiers, and evidence planning	Budget impact, cost-effectiveness, AMCP dossier, evidence gaps, PRO endpoints, and value story.	Adjacent. Therapeutic development services include patient/payer-demographic assessment and evidence-generation strategy; not a substitute for a dedicated HEOR shop.
Payer engagement and message testing	Ad boards, mock P&T, payer research, message testing, objection handling, and stakeholder mapping.	Adjacent. Reimbursement collateral and payer value proposition work is documented; confirm primary-research panel scope in RFP.
Policy, IRA, Medicaid, and channel strategy	IRA, Medicaid, 340B, Medicare, specialty channel, distribution, and policy-risk implications.	Core. First-mover positioning on Medicare Prescription Payment Plan (M3P) operational readiness and the $2,000 OOP cap under IRA.
Launch sequencing and execution support	Cross-functional launch planning, access playbooks, field tools, governance, and implementation support.	Core. Access Marketing & Creative Studio and RxAccess University formalize the launch-execution and field-enablement lanes.

Buyer Fit

• Best shortlist motion: Small-to-mid biotech launch teams that need senior-attention payer strategy, patient-support program design, and access-marketing materials from one boutique partner.
• Best-fit buyers: Emerging biotechs and mid-sized specialty manufacturers with one or two launches in flight; manufacturers needing supplier-diversity-qualified market-access partners.
• Less ideal fit: Large pharma needing global market-access scale; buyers requiring AET-style ex-payer panels or proprietary payer-data tools.
• Commercial fit: Custom/RFP; project SOWs with senior-operator engagement throughout.
• Validate before award: Specific senior operators assigned, M3P/IRA case examples, and how RxAccess hands off into hub and specialty-pharmacy partners.

Differentiators

• Senior-operator delivery model: 100+ years combined team experience; boutique scale means senior consultants stay on the work, not just on the pitch.
• Full payer-to-patient span: Single partner covers payer strategy, pricing, reimbursement collateral, and patient-support design; useful when buyers want to avoid stitching together three vendors.
• Woman-owned supplier-diversity status: Qualifies the firm for diversity-spend targets at large pharma buyers.
• M3P and IRA operational readiness: First-mover positioning on Medicare Prescription Payment Plan operational design and the $2,000 OOP cap.
• RxAccess University B2B SaaS: Productized payer-strategy, reimbursement, and patient-services curriculum, now a lead-generation engine for biopharma buyers.

RFP Questions

• Which senior operators will lead our engagement, and what launch analogs have they handled?
• Which payer inputs are primary research, standing panels, claims/formulary data, or consultant judgment?
• How does the firm convert payer strategy into specific account-team materials, hub workstreams, and field-reimbursement playbooks?
• What M3P and IRA operational-readiness work has been delivered in the past 12 months for analogous assets?
• How will RxAccess hand off into hub services, specialty pharmacy, and copay/PAP vendors?
• Which deliverables come from RxAccess University vs. custom engagement work?
• What pricing, contracting, and GTN modeling is in scope, and where does the firm hand off to a HEOR partner?

Recent Activity

• 2025 - First-mover positioning for Medicare Prescription Payment Plan (M3P) operational readiness and the $2,000 OOP cap under the IRA.
• 2024-2026 - Access Marketing & Creative Studio formalized as specialty marketing production lane for managed markets and specialty pharmacy hub models.
• 2024-2026 - RxAccess University transitioned from internal training tool to B2B SaaS lead-generation engine, productizing payer-strategy, reimbursement, and patient-services curriculum.
• 2024 - Digital brand presence launched (creative direction by Bryan Thatcher).
• 2023 - RxAccess Partners LLC formed to combine pharmaceutical market-access and patient-support skills into a full-spectrum boutique.